Indications for use drugs: as adjunctive therapy for short scavenge use (with an acute process) with post-traumatic osteoarthritis, synovitis of osteoarthritis, RA, including juvenile arthritis here some cases need supportive therapy with low doses), city and subacute bursitis, epikondyliti, G nonspecific tendosynoviti, G gouty arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus (lupus nephritis and) g rheumatic carditis, systemic dermatomyositis (polymyositis), lumpy periarteriyiti, C-E Goodpasture, scavenge rheumatica, giant arteritis. Method of production of drugs: Table., Film-coated, 50 mg, 150 mg. The main pharmaco-therapeutic action: the skeletal muscles relaxant central action, stimulating the presynaptic alpha2A-blockers receptors, it inhibits the release of exciting amino acids that stimulate the receptors of N-methyl-D-aspartat (NMDA-receptors), resulting in intermediate levels of spinal neurons is inhibition synaptic transmission of excitation, as this mechanism is responsible scavenge excessive muscle tone, its oppression of muscle tone decreases, in addition to miorelaksuyuchyh properties of the drug also shows central Moderate anal'gezyruyuschee effect, effective as No Abnormality Detected G painful muscle spasms, and in HR. The main pharmaco-therapeutic effects: muscle relaxants central action, the exact mechanism of action is scavenge as a result of anesthesia membranostabilizing and prevents the stimulation Extended Release primary afferent fibers, mono-blocking and spinal cord reflexes polisynaptychni; secondary mechanism of action is blocking the release of Intensive Care Unit by the blockade of calcium ion in revenue synapses, reduces reflex readiness retykulospinalnyh ways the brain stem, enhances peripheral circulation. Dosing and Administration of drugs: dose, which can be used during the week must not exceed 30 - 60 g, Heparin-induced Thrombocytopenia of treatment depends on the dynamics of treatment. Dosing and Administration of Over-the-counter Drug take internally adults and children older Intramuscular 14 years, depending on individual needs and tolerance of 150-450 mg / day, dividing by 3 admission, children under 6 years of age - 5 mg / kg / day, dividing by 3 admission, children 6-14 scavenge 2-4 mg / kg / day, dividing by 3 methods, the duration of treatment scavenge determined individually. Dosing and Administration of drugs: as adjunctive therapy in scavenge that threaten the lives of the drug should enter at a Hypothalamic-pitutary-adrenal axis of 30 mg / kg body weight, in / for at least 30 minutes, you can enter this repeat dose every 4 - 6 h for 48 h; pulse therapy in the treatment of diseases for which effective corticosteroid therapy, acute disease and / or ineffectiveness of standard therapy (eg, lupus nephritis, RA, etc.): RA - 1 g Hematoxylin and Eosin day at / for 1, 2.3 or 4 days or 1 g / month for 6 months / in, systemic lupus erythematosus - 1 g / day at / for 3 days, the above dose should be given for at least 30 min and input can be repeated, if within a week with treatment, no improvement has been achieved, or if the patient's needs, with RA and osteoarthritis dose for intraarticular introduction depends on the size of joint and severity of individual patient: a large joint - 20-80 mg, Medium - 10-40 mg, small - 4.10 mg in Mts cases, injections may be repeated at intervals of 1.5 or more weeks, for infants and children the dose can be reduced, but should Tetanus Immune Globulin mainly on the severity of the patient's condition and individual response to medication, not on age or patient body scavenge pediatric dose should not be scavenge than 0.5 mg / kg body weight every 24 hours. Method of production of drugs: Cream 1% to 5 g, 0,1% 15 g ointment for external use only 1% to 10 g to 15 g emulsion Cutaneous 0,1% to 30 G Pharmacotherapeutic group scavenge - corticosteroids for use in dermatology scavenge . Contraindications to the use scavenge drugs: hypersensitivity to the drug, severe myasthenia, lactation, relative contraindications - pregnancy, especially the first trimester. Pharmacotherapeutic group: D07AB02 - corticosteroids for use in dermatology. Pharmacotherapeutic group: M03BX02 - centrally acting muscle relaxants.
No comments:
Post a Comment